SECuRE Trial Update: First Patient Treated in New Phase
HIGHLIGHTS
- The first participant in the Cohort Expansion Phase (Phase II) of the SECuRE trial has received their initial dose of 8 GBq of 67Cu-SAR-bisPSMA. This step follows a recommendation from the Safety Review Committee to advance after a successful Dose Escalation Phase.
- This treatment includes a combination of 8 GBq of 67Cu-SAR-bisPSMA and enzalutamide, an androgen receptor pathway inhibitor, following recent updates to the trial protocols.
- Prior to this phase, Clarity Pharmaceuticals introduced an improved formulation of 67Cu-SAR-bisPSMA, enhancing its stability and scalability, which are critical for clinical trials and future manufacturing efforts.
Clarity Pharmaceuticals (ASX: CU6), a clinical-stage radiopharmaceutical company dedicated to improving cancer treatment outcomes, is thrilled to share that the first participant has been treated in the Cohort Expansion Phase of the SECuRE trial with a dosage of 8 GBq of 67Cu-SAR-bisPSMA. This follows the conclusion of the earlier Dose Escalation Phase, where the Safety Review Committee provided guidance for this next step.
This recent participant is undergoing treatment with both 67Cu-SAR-bisPSMA and enzalutamide, thanks to a recent protocol amendment that allows a select group of participants to receive this combination therapy. The trials broadened their enrollment criteria, increasing participant numbers from 14 to 24, incorporating advancements from the Enza-p trial and input from esteemed global medical professionals specializing in prostate cancer therapy.
The revamped SECuRE trial will place a strong emphasis on assessing participants with metastatic castration-resistant prostate cancer (mCRPC) prior to chemotherapy. This focus aligns with Clarity's strategic aim to explore the benefits of 67Cu-SAR-bisPSMA at earlier cancer stages. Evidence from earlier cohorts has demonstrated notable reductions in prostate-specific antigen (PSA) levels, with significant drops observed in this challenging patient group.
Clarity recently launched the improved formulation of 67Cu-SAR-bisPSMA, designed to enhance stability and availability for clinical application, which is vital for the success of upcoming phases of the trial.
Dr. Alan Taylor, Executive Chairperson of Clarity, expressed enthusiasm regarding the advancements achieved in the SECuRE trial, affirming their commitment to following the latest clinical research trends to drive successful patient outcomes. He highlighted their dedication to working with key opinion leaders in the field and maximizing the efficiency of their clinical trial management practices.
Dr. Taylor elaborated on the importance of reformulating their product ahead of patient treatment, preparing for future phases and large-scale manufacturing that guarantees room temperature stability, thus reducing common issues such as batch failures. By implementing this improved formulation, the organization aims to ensure timely treatment for patients requiring the 67Cu-SAR-bisPSMA therapy.
Clarity has expressed heartfelt gratitude to the community, their team, and every participant contributing to the SECuRE study. With three Fast Track Designations from the FDA for the SAR-bisPSMA molecule, Clarity is closer than ever to fulfilling their mission of enhancing cancer treatment outcomes.
Unveiling the SECuRE Trial
The SECuRE trial (NCT04868604) represents a Phase I/IIa theranostic initiative aimed at treating patients with PSMA-expressing mCRPC using 64Cu/67Cu-SAR-bisPSMA. This unique approach utilizes 64Cu-SAR-bisPSMA for imaging, helping identify candidates for the subsequent 67Cu-SAR-bisPSMA therapy. The multi-centre trial aims to gather safety and efficacy data involving approximately 54 participants across various locations.
Understanding SAR-bisPSMA
SAR-bisPSMA emerges from the innovative integration of two PSMA-targeting agents within Clarity's proprietary SAR technology framework, which effectively encapsulates copper isotopes. This distinctive methodology ensures that copper does not leach into the body, differentiating it from other available options.
Prostate Cancer Insights
Prostate cancer ranks as the second most diagnosed cancer among men worldwide and the fifth leading cause of cancer-related fatalities among men. Current estimations from health authorities predict a significant number of new cases and fatalities, underscoring the importance of innovative treatments.
About Clarity Pharmaceuticals
Clarity Pharmaceuticals stands at the forefront of developing advanced radiopharmaceuticals, focusing on treating serious diseases through its Targeted Copper Theranostics approach. Their ongoing commitment to innovation positions them as leaders in cancer treatment.
Frequently Asked Questions
What is the SECuRE trial?
The SECuRE trial is a Phase I/IIa study testing 67Cu-SAR-bisPSMA for treating patients with prostate cancer to assess its safety and efficacy.
Who is leading the SECuRE trial?
Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company, is conducting the SECuRE trial focusing on innovative treatment solutions.
What is 67Cu-SAR-bisPSMA?
67Cu-SAR-bisPSMA is a radiopharmaceutical designed for treating prostate cancer, part of Clarity's theranostic approach that also involves imaging with 64Cu.
Why is the trial significant?
This trial could pave the way for new treatment standards in advanced prostate cancer, potentially improving outcomes for patients who do not respond to traditional therapies.
How will Clarity benefit from the trial?
Through positive trial outcomes, Clarity could enhance its product offerings and solidify its position as an innovator in the cancer treatment landscape.
